Understand the EBITDA multiples, value drivers, and deal structures that determine what private equity roll-ups and physician buyers will pay for an independent dermatology practice.
Find Dermatology Practice Businesses For SaleDermatology practices are typically valued on a multiple of EBITDA, reflecting the specialty's high margins, dual medical-and-cosmetic revenue model, and strong demand from private equity consolidators. Practices with $1M or more in EBITDA, multiple licensed providers, and a meaningful cosmetic revenue mix routinely command premiums in the 5x–7x EBITDA range. The highly fragmented nature of the U.S. dermatology market — with thousands of independent practices — continues to drive competitive acquisition activity and supports above-average multiples compared to many other medical specialties.
4×
Low EBITDA Multiple
5.5×
Mid EBITDA Multiple
7×
High EBITDA Multiple
Lower multiples (4x–5x EBITDA) apply to solo-physician practices with heavy Medicare dependency, aging equipment, or no mid-level provider support. Mid-range multiples (5x–6x) reflect practices with $750K–$1.5M EBITDA, mixed payer profiles, and some cosmetic revenue. Top-tier multiples (6x–7x+) are reserved for multi-provider practices with $1M+ EBITDA, strong cash-pay cosmetic revenue streams, clean malpractice history, and modern infrastructure that fits neatly into a private equity roll-up platform.
$3,200,000
Revenue
$1,100,000
EBITDA
5.8x
Multiple
$6,380,000
Price
Asset purchase using an MSO structure to comply with state corporate practice of medicine laws. Financed with an SBA 7(a) loan covering approximately 75% of the purchase price, a 12% seller note ($765,600) with a 5-year repayment term, and an earnout component tied to EBITDA performance over 24 months post-close. The founding dermatologist agreed to a 24-month employment transition at market compensation with a non-compete covering a 15-mile radius for 3 years post-employment. Physician equity rollover of 10% into the acquiring platform entity was included to align post-close incentives.
EBITDA Multiple (Primary Method)
The dominant valuation method for dermatology practices. A buyer calculates trailing twelve-month EBITDA — normalizing for owner compensation, personal expenses, and one-time costs — and applies a market multiple. For dermatology, this typically ranges from 4x to 7x depending on practice size, provider mix, and revenue quality. Cosmetic revenue often receives favorable weighting due to its higher margins and cash-pay nature.
Best for: Practices with $500K+ in annual EBITDA seeking acquisition by private equity platforms, physician roll-ups, or SBA-financed individual buyers
Revenue Multiple
A secondary or sanity-check method sometimes used when EBITDA is temporarily suppressed due to physician transition, equipment investment, or staffing changes. Dermatology practices may trade at 0.8x–1.5x annual revenue depending on the proportion of cosmetic versus medical revenue and overall profitability. Cash-pay cosmetic-heavy practices trend toward the top of this range.
Best for: Early-stage valuation discussions, distressed practices, or situations where EBITDA is not representative of normalized earning power
Discounted Cash Flow (DCF)
A forward-looking method that projects future free cash flows — accounting for reimbursement trends, expected patient volume growth, planned capital expenditures, and provider capacity — and discounts them to present value. Less common in lower middle market dermatology deals but increasingly used by PE platforms modeling 5-year hold returns on larger acquisitions.
Best for: PE-backed acquirers underwriting multi-practice roll-up platforms where synergies, add-on acquisitions, and growth investments are part of the investment thesis
Asset-Based Valuation
Values the practice based on tangible assets including dermatology equipment (lasers, phototherapy units, Mohs surgery equipment), leasehold improvements, and accounts receivable. Rarely used as a standalone method for a going-concern dermatology practice, but relevant in wind-down scenarios or when equipment replacement costs are a significant negotiation point.
Best for: Distressed practices, asset sale negotiations, or as a floor valuation when goodwill and patient relationships have limited transferability
Strong Cosmetic Revenue Mix
Practices generating 25%–40% or more of revenue from cash-pay cosmetic services — including Botox, dermal fillers, laser treatments, and chemical peels — command premium multiples. These services carry gross margins well above insurance-reimbursed medical dermatology and are insulated from payer reimbursement cuts, making them highly attractive to acquirers building durable EBITDA.
Multiple Licensed Providers
Practices staffed with two or more board-certified dermatologists or a supervising dermatologist supported by experienced PAs or NPs are dramatically more valuable than solo-physician operations. Multi-provider practices reduce key-person risk, demonstrate scalable capacity, and are far easier to underwrite from a buyer's perspective since revenue is not entirely dependent on one individual's continued presence post-close.
Diversified and Favorable Payer Mix
A balanced payer mix — with commercial insurance representing the majority of revenue, Medicare under 40%, and a meaningful cash-pay cosmetic component — signals revenue stability and limits exposure to government reimbursement compression. Practices with long-term commercial payer contracts and documented reimbursement rates are viewed as lower-risk and command better terms.
Documented, Recurring Patient Base
High patient retention rates, a large active patient panel, and recurring appointment volume from chronic skin condition management (e.g., psoriasis, eczema, acne) create predictable revenue. Practices with strong online reputations, positive Google and Healthgrades reviews, and low no-show rates signal operational health and a defensible patient base that will transfer with the practice.
Modern Facility and Up-to-Date Equipment
A clean, well-maintained facility with current-generation dermatology equipment — including Mohs surgery capability, modern laser platforms, and a functional aesthetic suite — reduces the capital expenditure burden a buyer must absorb post-acquisition. Practices with a lease that has 3+ years remaining and favorable renewal options remove a significant deal risk for acquirers.
Clean Revenue Cycle and Billing History
Practices with low claims denial rates, strong collections ratios (95%+), and minimal outstanding AR over 90 days demonstrate operational discipline that accelerates buyer confidence. Clean revenue cycle management reduces integration costs and signals that the practice is not masking billing compliance risks or payer disputes that could surface post-close.
Single-Physician Revenue Concentration
If one dermatologist accounts for 80% or more of practice revenue with no established mid-level provider support or succession plan, most PE buyers will either reprice the deal significantly or walk away. This concentration creates unacceptable key-person risk — particularly if that physician is retiring — and limits the buyer's ability to protect revenue through non-compete agreements alone.
Pending or Unresolved Malpractice Claims
Outstanding malpractice claims, state medical board investigations, or a pattern of prior litigation will trigger deep buyer scrutiny and often result in deal renegotiation or termination. Buyers will demand tail coverage clarity, occurrence vs. claims-made policy documentation, and may escrow a portion of proceeds pending claim resolution. Unresolved matters discovered in due diligence are among the most common deal-killers in physician practice M&A.
High Medicare and Medicaid Concentration
Practices where Medicare and Medicaid collectively represent 50%+ of revenue face meaningful exposure to ongoing reimbursement rate compression, coding audits, and policy changes. Buyers will apply lower multiples to reflect this risk, and SBA lenders may scrutinize government payer dependency when underwriting acquisition financing.
Inconsistent or Declining Revenue Trends
A practice showing flat or declining revenue over the prior 24–36 months — without a clear, documented explanation such as a provider departure or COVID disruption — signals potential patient attrition, competitive pressure, or operational problems. Buyers will stress-test downside scenarios heavily and are unlikely to pay full market multiples without a credible growth narrative backed by data.
Expiring Lease or Facility Issues
A lease expiring within 12 months of closing — without a signed renewal or viable relocation plan — is a significant deal obstacle. Buyers financing through SBA lenders are typically required to show lease terms extending at least through the loan repayment period. Poor facility condition, ADA compliance issues, or an unfavorable lease assignment clause can each independently derail a transaction.
Outdated EMR and Practice Management Systems
Legacy EMR platforms, paper-based records, or practice management software incompatible with acquirer systems create expensive and time-consuming integration challenges. For PE-backed roll-up buyers standardizing on a single platform across their portfolio, an outdated technology stack is a direct hit to post-close integration costs and may be reflected in a lower offer price or deal structure.
Find Dermatology Practice Businesses For Sale
Signal-scored targets with seller motivation, multiples, and outreach — free to join.
Most independent dermatology practices in the lower middle market trade between 4x and 7x EBITDA. Solo-physician practices with heavy Medicare dependency and limited cosmetic revenue typically land in the 4x–5x range. Multi-provider practices with $1M+ EBITDA, a meaningful cash-pay cosmetic mix, and clean financials regularly achieve 5.5x–7x — particularly when being acquired by a PE-backed roll-up platform competing against other strategic buyers.
Cosmetic revenue — from services like Botox, fillers, laser treatments, and body contouring — significantly enhances practice valuation because it carries higher gross margins than insurance-reimbursed medical dermatology and is not subject to payer reimbursement cuts. Buyers typically view a well-documented cosmetic revenue stream as a premium asset. Practices where cosmetic services represent 25% or more of total revenue often command multiples at the higher end of the market range, provided the revenue is recurring and tied to the practice rather than a single provider.
Yes. Dermatology practices are SBA-eligible businesses, and SBA 7(a) loans are commonly used to finance acquisitions in this space. A qualified buyer can typically finance up to 90% of the purchase price through an SBA 7(a) loan, with the remaining 10% covered by a seller note or buyer equity injection. Lenders will scrutinize payer mix, physician retention risk, and EBITDA stability during underwriting. Practices with heavy government payer concentration or pending physician departures may face more restrictive loan terms or require additional collateral.
An MSO — Management Services Organization — is a legal structure used in many dermatology acquisitions to comply with state corporate practice of medicine (CPOM) laws, which prohibit non-physician entities from directly owning a medical practice in many states. Under an MSO structure, a non-physician buyer (such as a PE firm or management company) owns the management company that handles administrative, billing, and operational functions, while a physician-owned professional corporation (PC) retains ownership of the clinical entity. This structure is standard in PE-backed dermatology roll-ups and is important for buyers to understand before structuring any offer.
Most dermatology practice sales in the lower middle market take between 12 and 24 months from the decision to sell through to closing. The timeline includes exit preparation (typically 3–6 months to clean up financials, organize documents, and address value killers), marketing to qualified buyers (2–4 months), letter of intent negotiation and due diligence (3–6 months), and final transaction documentation and closing (1–2 months). Sellers who begin exit planning early — particularly around physician succession, malpractice tail coverage, and lease renewal — consistently achieve better outcomes and faster closings.
The five areas buyers scrutinize most heavily are: (1) physician employment agreements and non-compete enforceability — specifically whether the selling physician and any associates are contractually bound post-close; (2) payer contracts and revenue cycle quality — including denial rates, collections history, and reimbursement rates by payer; (3) malpractice history — occurrence vs. claims-made policy structure, tail coverage obligations, and any open claims or board actions; (4) corporate practice of medicine compliance — ensuring the deal structure is legally sound in the applicable state; and (5) patient volume trends — particularly the ratio of medical to cosmetic appointments and any concentration of revenue around a single provider.
Buyers and their financial advisors will want to see at least 36 months of revenue segmented by service category — specifically medical dermatology (insurance-billed), surgical dermatology (Mohs, excisions), and cosmetic/aesthetic services (cash-pay Botox, fillers, lasers, etc.). Each segment has different margin profiles and risk characteristics, and buyers will value them differently. Work with your accountant or healthcare M&A advisor to build a clean revenue bridge that separates these streams, documents associated direct costs, and shows normalized EBITDA by segment. This exercise alone can meaningfully increase your valuation by demonstrating the premium cosmetic revenue component.
More Dermatology Practice Guides
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers